Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC Vaccine

EMERYVILLE, Calif.: EMERYVILLE, Calif., Aug. 20, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced promising in-vivo results in a study of its licensed...

Click to view original post